Identification

Name
Ethotoin
Accession Number
DB00754  (APRD00962)
Type
Small Molecule
Groups
Approved
Description

Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.

Structure
Thumb
Synonyms
  • (+-)-3-Ethyl-5-phenylhydantoin
  • 1-Ethyl-2,5-dioxo-4-phenylimidazolidine
  • 3-Ethyl-5-phenyl-2,4-imidazolidinedione
  • 3-Ethyl-5-phenyl-imidazolidine-2,4-dione
  • 3-Ethyl-5-phenylhydantoin
  • 3-Ethyl-5-phenylimidazolidin-2,4-dione
  • Ethotoin
  • Ethotoïne
  • Ethotoinum
  • Etotoina
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PeganoneTablet250 mg/1OralRecordati Rare Diseases Inc1957-04-222018-08-31Us
PeganoneTablet250 mg/1OralRecordati Rare Diseases Inc1957-04-22Not applicableUs
International/Other Brands
Accenon (Dainippon Sumitomo) / Pegoanone
Categories
UNII
46QG38NC4U
CAS number
86-35-1
Weight
Average: 204.2252
Monoisotopic: 204.089877638
Chemical Formula
C11H12N2O2
InChI Key
SZQIFWWUIBRPBZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
IUPAC Name
3-ethyl-5-phenylimidazolidine-2,4-dione
SMILES
CCN1C(=O)NC(C1=O)C1=CC=CC=C1

Pharmacology

Indication

For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.

Associated Conditions
Pharmacodynamics

Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.

Mechanism of action

The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation.

TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Human
UNuclear receptor subfamily 1 group I member 2
activator
Human
Absorption

Fairly rapidly absorbed, however, the extent of oral absorption is not known.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic. The drug exhibits saturable metabolism with respect to the formation of N-deethyl and p-hydroxyl-ethotoin, the major metabolites.

Route of elimination
Not Available
Half life

3 to 9 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with 7-Nitroindazole.Experimental
AcenocoumarolEthotoin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethotoin.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethotoin.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethotoin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ethotoin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethotoin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Azaperone.Investigational, Vet Approved
AzelastineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ethotoin.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethotoin is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethotoin.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Bupivacaine.Approved, Investigational
BuprenorphineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethotoin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ethotoin.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethotoin is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Ethotoin is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethotoin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethotoin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ethotoin is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethotoin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethotoin.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethotoin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethotoin.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ethotoin.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ethotoin.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ethotoin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethotoin.Approved, Illicit
ClorindioneEthotoin may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethotoin.Approved
CocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethotoin.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethotoin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethotoin.Approved, Illicit, Investigational, Vet Approved
DicoumarolEthotoin may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ethotoin is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethotoin.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.Approved
DiphenadioneEthotoin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethotoin.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethotoin.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Ethotoin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethotoin is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ethotoin.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethotoin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethotoin.Approved, Investigational
EthanolEthotoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethotoin.Approved
Ethyl biscoumacetateEthotoin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethotoin.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fludiazepam.Approved, Illicit
FluindioneEthotoin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethotoin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethotoin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethotoin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethotoin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethotoin is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethotoin.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ethotoin is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Hexobarbital.Approved
HydrocodoneEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethotoin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethotoin.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethotoin.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethotoin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Lidocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Ethotoin is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Ethotoin is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Ethotoin can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ethotoin.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethotoin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Ethotoin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Ethotoin is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ethotoin.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Ethotoin is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethotoin.Approved
MethotrimeprazineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methylphenobarbital.Approved
MetyrosineEthotoin may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethotoin is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Investigational
MirtazapineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethotoin.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethotoin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethotoin.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethotoin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethotoin is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Ethotoin can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineEthotoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethotoin is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethotoin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Ethotoin is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethotoin.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.Approved
ParaldehydeEthotoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethotoin.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethotoin is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethotoin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethotoin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethotoin is combined with Phenibut.Experimental
PhenindioneEthotoin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethotoin.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Phenoxyethanol.Approved
PhenprocoumonEthotoin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ethotoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.Approved
PramipexoleEthotoin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Ethotoin can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ethotoin is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethotoin.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ethotoin is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethotoin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethotoin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Romifidine.Vet Approved
RopiniroleEthotoin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ropivacaine.Approved
RotigotineEthotoin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethotoin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ethotoin.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethotoin.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sultopride.Experimental
SuvorexantEthotoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethotoin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrodotoxin.Investigational
ThalidomideEthotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ethotoin is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethotoin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethotoin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tilidine.Experimental
TioclomarolEthotoin may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ethotoin.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ethotoin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethotoin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ethotoin is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethotoin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ethotoin.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Ethotoin is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vortioxetine.Approved, Investigational
WarfarinEthotoin may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Ethotoin is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethotoin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zolazepam.Vet Approved
ZolpidemEthotoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethotoin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories.

General References
  1. SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. [PubMed:13317788]
External Links
Human Metabolome Database
HMDB0014892
KEGG Drug
D00708
KEGG Compound
C07839
PubChem Compound
3292
PubChem Substance
46504521
ChemSpider
3176
ChEBI
4888
ChEMBL
CHEMBL1095
Therapeutic Targets Database
DAP000512
PharmGKB
PA164768735
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ethotoin
ATC Codes
N03AB01 — Ethotoin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Lundbeck inc
Packagers
  • Abbott Laboratories Ltd.
  • Kaiser Foundation Hospital
  • Lundbeck Inc.
Dosage forms
FormRouteStrength
TabletOral250 mg/1
Prices
Unit descriptionCostUnit
Peganone 250 mg tablet1.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)94 °CPhysProp
water solubility5280 mg/LNot Available
logP1.05SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility2.38 mg/mLALOGPS
logP1.11ALOGPS
logP1.07ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)11.29ChemAxon
pKa (Strongest Basic)-8.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.41 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity55.05 m3·mol-1ChemAxon
Polarizability20.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9936
Caco-2 permeable+0.5629
P-glycoprotein substrateNon-substrate0.592
P-glycoprotein inhibitor INon-inhibitor0.8358
P-glycoprotein inhibitor IINon-inhibitor0.9401
Renal organic cation transporterNon-inhibitor0.8532
CYP450 2C9 substrateNon-substrate0.7507
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7383
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.914
CYP450 2D6 inhibitorNon-inhibitor0.9619
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8591
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8483
Ames testNon AMES toxic0.7056
CarcinogenicityNon-carcinogens0.8655
BiodegradationNot ready biodegradable0.8423
Rat acute toxicity2.1653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.886
hERG inhibition (predictor II)Non-inhibitor0.8724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-6980000000-86b5edde33787fa5b3d5
GC-MS Spectrum - EI-BGC-MSsplash10-0zfr-4920000000-137fae4223f8b51dd5cd
GC-MS Spectrum - CI-BGC-MSsplash10-0a4i-1190000000-3ade8f65bbabe08f852a
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-1190000000-56ad3615dcbc3fbecdbc
Mass Spectrum (Electron Ionization)MSsplash10-0udi-6920000000-01714c9dcd6c4cf02362
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1900000000-f71513d432cabc6ae596

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylhydantoins
Alternative Parents
Phenylimidazolidines / Alpha amino acids and derivatives / N-acyl ureas / Benzene and substituted derivatives / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
5-phenylhydantoin / Phenylimidazolidine / Alpha-amino acid or derivatives / N-acyl urea / Ureide / Monocyclic benzene moiety / Benzenoid / Dicarboximide / Urea / Carbonic acid derivative
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazolidine-2,4-dione (CHEBI:4888)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Lenkowski PW, Ko SH, Anderson JD, Brown ML, Patel MK: Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. Eur J Pharm Sci. 2004 Apr;21(5):635-44. [PubMed:15066664]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K: Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos. 2004 Apr;32(4):468-72. [PubMed:15039302]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:23